| Parameter | Specification |
|---|---|
| Model | 3-5N |
| Max Speed | 5000rpm |
| Max RCF | 4390xg |
| Max Capacity | 4*50ml (Syringe) |
| Speed Accuracy | ±20r/min |
| Timing Range | 1s ~ 99min (Programmable) |
| Total Power | 750W |
| Noise | <60dB(A) |
| Dimensions (L*W*H) | 540*460*400mm |
| Net Weight | 50kg |
| Power Supply | AC 220±22V, 50Hz |
Our 3-5N centrifuge is engineered based on the widely recognized Coleman technique principles, where controlled speed and time are critical for maintaining adipocyte viability. Unlike conventional clinical centrifuges, our model features a proprietary cooling system that prevents thermal damage to delicate fat cells.
We prioritize equipment longevity and sample integrity by using 304 stainless steel and providing maintenance-free drive systems. This ensures your investment yields consistent, high-quality results, making it the smart choice for labs aiming for clinical excellence.
Contact our B2B sales team today for bulk pricing, OEM inquiries, or to request a sample test. Our experts are ready to assist you with technical specifications and custom configurations.
Get a Quote Now!
The global autologous fat grafting market is valued at approximately $411 million in 2024 and projected to reach $587 million by 2031, driven by a 9.7% CAGR in facial fat transfer procedures.
Current Trend: Industry standard often cites 3,000 rpm, but experts now emphasize that Relative Centrifugal Force (RCF/xg) is critical for reproducibility.
Our Advantage: The 3-5N allows precise parameter adjustments, enabling labs to replicate optimal protocols (1,054g or 1,286g) supported by recent studies for high viability.
Current Trend: Many standard lab centrifuges lack specific thermal management for fat, leading to friction heat that damages adipocytes.
Our Advantage: The 3-5N's dedicated heat dissipation system ensures the cavity does not heat up, preserving fat cell structural integrity and maximizing graft retention.
Current Trend: Market is moving toward specialized systems, but devices like Puregraft and Revolve represent high-cost capital investment (approx. $50k).
Our Advantage: The 3-5N offers specialized solution at a fraction of the cost, supporting syringe compatibility and reducing cost per procedure by replacing expensive disposable kits.
